Trexquant Investment LP Has $3.67 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Trexquant Investment LP lifted its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 93.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 462,720 shares of the company's stock after acquiring an additional 223,158 shares during the quarter. Trexquant Investment LP owned approximately 0.15% of Amneal Pharmaceuticals worth $3,665,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMRX. Mirae Asset Global Investments Co. Ltd. bought a new position in Amneal Pharmaceuticals during the fourth quarter worth about $81,000. Cibc World Markets Corp acquired a new position in Amneal Pharmaceuticals during the fourth quarter valued at approximately $118,000. Janney Montgomery Scott LLC bought a new stake in Amneal Pharmaceuticals in the fourth quarter valued at approximately $121,000. Fox Run Management L.L.C. raised its holdings in Amneal Pharmaceuticals by 69.0% in the fourth quarter. Fox Run Management L.L.C. now owns 20,435 shares of the company's stock worth $162,000 after purchasing an additional 8,342 shares during the period. Finally, Quadrature Capital Ltd bought a new position in shares of Amneal Pharmaceuticals during the third quarter worth $169,000. 31.82% of the stock is owned by institutional investors.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the transaction, the insider now directly owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. The trade was a 9.33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gautam Patel sold 80,000 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total transaction of $712,000.00. Following the completion of the sale, the director now owns 1,808,886 shares of the company's stock, valued at approximately $16,099,085.40. This represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,160,000 shares of company stock worth $43,113,200. Insiders own 26.56% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on AMRX. Barclays upped their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a research report on Monday, March 3rd. StockNews.com lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, December 19th. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $9.00 to $12.00 in a research report on Monday, February 24th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $10.80.

Amneal Pharmaceuticals Trading Up 0.1 %

Shares of AMRX stock traded up $0.01 on Friday, hitting $6.98. 1,807,041 shares of the stock were exchanged, compared to its average volume of 1,401,811. The firm has a market capitalization of $2.16 billion, a P/E ratio of -10.26 and a beta of 1.06. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $5.18 and a fifty-two week high of $9.48. The business has a 50-day moving average of $8.17 and a 200 day moving average of $8.28.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The business had revenue of $730.52 million for the quarter, compared to the consensus estimate of $708.21 million. During the same period in the prior year, the business earned $0.14 earnings per share. As a group, research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.